Examkin

Question

Difficulty: Very hardRheumatology and Immunology

A 42-year-old woman is newly diagnosed with limited cutaneous systemic sclerosis. She is highly anxious about the potential progression of her Raynaud phenomenon, which currently manifests as mild, infrequent vasospastic episodes triggered by cold exposure. During her clinic visit, she asks about the long-term management strategy for this condition if her symptoms worsen over time. You outline a stepwise therapeutic escalation pathway. Arrange the following management steps in the correct chronological order of therapeutic escalation, from the initial foundational intervention to the final rescue treatment for medically refractory, critical digital ischemia.

  1. 1Implementation of comprehensive behavioral modifications, including core body warming and smoking cessation
  2. 2Initiation of an oral dihydropyridine calcium channel blocker (e.g., amlodipine)
  3. 3Addition of an oral phosphodiesterase-5 inhibitor (e.g., sildenafil)
  4. 4Admission for an intravenous prostanoid infusion (e.g., iloprost or epoprostenol)
  5. 5Referral for localized digital sympathectomy

Answer

The correct escalation of therapy is: 1) Behavioral modifications, 2) Oral calcium channel blocker, 3) Oral phosphodiesterase-5 inhibitor, 4) Intravenous prostanoid, 5) Digital sympathectomy.
The management of secondary Raynaud phenomenon in systemic sclerosis follows a strict escalating pathway based on symptom severity and tissue viability. It begins with essential lifestyle modifications (avoiding cold and vasoconstrictors like nicotine). If attacks persist, a dihydropyridine calcium channel blocker (amlodipine, nifedipine) is the first-line oral medication. For refractory symptoms, step-up combination therapy includes adding a phosphodiesterase-5 inhibitor (sildenafil) or an endothelin receptor antagonist. If the disease progresses to severe digital ischemia or active ulceration, intravenous prostanoids (iloprost, epoprostenol) are indicated. Finally, if all medical therapies fail and there is impending gangrene, localized digital sympathectomy serves as the last resort to salvage the digit.

Step-by-Step Solution

1
Identify the primary condition and its common complications.
The patient has limited cutaneous systemic sclerosis, which is universally associated with Raynaud phenomenon.
Understanding the natural history of systemic sclerosis-associated Raynaud phenomenon is required to anticipate the need for escalating therapy.
2
Determine the foundational treatment for mild Raynaud phenomenon.
Behavioral modifications (avoiding cold, keeping the core warm, smoking cessation) are always the first step.
Non-pharmacologic interventions can adequately manage mild disease and remove triggers of vasospasm.
3
Identify the first-line pharmacologic therapy for symptoms refractory to lifestyle changes.
Oral dihydropyridine calcium channel blockers (e.g., amlodipine, nifedipine) are initiated.
These agents promote smooth muscle relaxation and peripheral vasodilation, proving highly effective for most patients.
4
Determine the next step for inadequately controlled symptoms despite initial pharmacotherapy.
Addition of a phosphodiesterase-5 inhibitor (e.g., sildenafil).
Combination oral vasodilator therapy is indicated before progressing to invasive or intravenous treatments.
5
Identify the management for severe, tissue-threatening complications (e.g., digital ulcers).
Intravenous prostanoids (e.g., iloprost).
When oral therapies fail to prevent critical ischemia or ulceration, potent intravenous vasodilators and platelet inhibitors are required.
6
Determine the treatment of last resort for critical, medically refractory ischemia.
Surgical digital sympathectomy.
If maximal medical therapy fails and the digit is at risk of necrosis or amputation, sympathectomy is performed to remove autonomic vasoconstrictive tone.

Key Concept

The stepwise management of systemic sclerosis-associated Raynaud phenomenon progresses from lifestyle modifications to oral vasodilators (CCBs, then PDE-5 inhibitors), to intravenous prostanoids for severe ischemia, and finally surgical sympathectomy for refractory critical ischemia.
Estimated Time:1m 30s
Rate this question

Topics

Rheumatology and Immunology

More questions from this topic